


Semaglutide SF operates as a telehealth-focused weight loss clinic serving patients throughout San Francisco, California, with medical supervision of GLP-1 receptor agonist therapies. The clinic provides access to three FDA-approved medications—liraglutide, semaglutide, and tirzepatide—each prescribed based on individual metabolic profiles, weight loss goals, and medical history. Patients undergo initial consultations via secure video platform where providers review lab work, assess contraindications, and establish baseline metrics including body composition, fasting glucose, and lipid panels before initiating treatment.
The clinic's treatment protocols center on GLP-1 receptor agonists that regulate appetite, slow gastric emptying, and improve insulin sensitivity. Liraglutide is typically prescribed as a daily subcutaneous injection starting at 0.6 mg with gradual titration to therapeutic doses, while semaglutide follows a weekly injection schedule beginning at 0.25 mg. Tirzepatide, a dual GIP/GLP-1 receptor agonist, is reserved for patients requiring more robust metabolic intervention or those with concurrent type 2 diabetes. Each medication requires patient education on proper injection technique, refrigeration requirements, and management of common side effects including nausea and gastrointestinal adjustment during dose escalation phases.
Semaglutide SF structures its programs around monthly telehealth check-ins where providers monitor weight trends, adjust dosing schedules, and address any adverse reactions or plateau periods. The clinic requires patients to submit updated weight logs and photographs for progress documentation, with lab work repeated at three-month intervals to track changes in hemoglobin A1C, liver enzymes, and thyroid function. Providers evaluate each patient's response to therapy and make medication switches when initial agents prove ineffective or poorly tolerated, ensuring continuity of care without requiring in-person office visits across the San Francisco Bay Area.
Patients receive medication shipped directly to their San Francisco addresses in temperature-controlled packaging, with syringes, alcohol swabs, and sharps containers included in each monthly supply. The clinic provides written injection protocols and video demonstrations for first-time users of subcutaneous peptides, along with 24-hour messaging access for urgent questions about dosing errors or unexpected symptoms. Follow-up appointments address behavioral components of weight management, including meal timing strategies that complement GLP-1 mechanisms and exercise recommendations that preserve lean muscle mass during caloric deficit periods.
The telehealth model eliminates geographic barriers for San Francisco residents in neighborhoods from the Marina to the Mission District, allowing patients to maintain treatment continuity despite work schedules or mobility limitations. Semaglutide SF accepts limited insurance plans for GLP-1 medications when prescribed for type 2 diabetes with BMI criteria met, while weight loss indications typically require out-of-pocket payment with transparent pricing disclosed during initial consultations. The clinic maintains a focused scope of practice centered exclusively on GLP-1 therapies rather than offering broad functional medicine services, ensuring provider expertise remains concentrated on peptide-based metabolic interventions and their specific monitoring requirements.
Dr. Miller, MD
Physician
Dr. Miller is a licensed physician providing physician-guided weight loss and metabolic health care aligned with recognized clinical guidelines. He received his medical degree from Columbia University and completed postgraduate training at Washington University in St. Louis. Dr. Miller conducts personalized medical evaluations and may prescribe treatment when appropriate.
Dr. Niles, MD
Physician
Dr. Niles is a licensed physician with over 30 years of clinical experience who provides physician-guided weight loss consultations centered on personalized care. She evaluates each patient’s medical history and individual goals to determine appropriate treatment options when indicated.
Dr. Krasne, MD
Physician
Dr. Krasne is a board-certified physician who conducts personalized weight loss evaluations and provides physician-guided care. He completed his medical training at the University of Florida and the University of Miami Miller School of Medicine, with residency completed in 2017. When clinically appropriate, he may prescribe GLP-1 medications based on individual health needs.
Dr. Bugailiskis, MD
Physician
Dr. Bugailiskis is a licensed physician who provides personalized, physician-guided weight loss care. She earned her medical degree from the University of Illinois at Chicago and works with patients to evaluate their health history, goals, and clinical needs when determining appropriate treatment options.
MyPeptideMatch.com is an independent directory. We do not provide medical advice. Always consult a qualified healthcare provider before starting any peptide therapy.


